**Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention**

Kaivan Vaidya1,a, Bradley Tucker2,3,a, Rahul Kurup1,2, Chinmay Khandkar1, Elvis Pandzic4, Jennifer Barraclough1,2, Ashish Misra2, Mary Kavurma2, Gonzalo Martinez5, Kerry-Anne Rye3, Blake J Cochran3,b, Sanjay Patel1,2,6,b.

a These authors contributed equally and share first authorship.

b These authors contributed equally and share senior authorship.

**Affiliations:**

1 Royal Prince Alfred Hospital, Sydney, Australia

2 Heart Research Institute, Sydney, Australia

3 School of Medical Sciences, UNSW Sydney, Sydney, Australia

4 Biomedical Imaging Facility, Mark Wainwright Analytical Centre, UNSW Sydney, Sydney, Australia

5 Division of Cardiovascular Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile

6 Sydney Medical School, University of Sydney, Sydney, Australia

**Supplementary Table 1: Method of peripheral venous and coronary sinus blood sampling.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Stage** | Pre-PCI | Post-angioplasty | Post-stenting | Post-stenting | Post-stenting |
| **Time** | 0 | 45 s | 1 min 30 s | 2 min 15 s | 3 min |
| **Coronary sinus** | **•** | **•** | **•** | **•** | **•** |
| **Peripheral venous** | **•** | x | x | x | **•** |

x = no sample collected

**Supplementary Table 2: Baseline demographic, clinical and angiographic characteristics of *ex vivo* cohort.**

|  |  |
| --- | --- |
| **Characteristics**  | **Count** |
| Age (n=11) | 71.5 (±14.2) |
| Sex (male) (n=11) | 7 (63.6%) |
| Presentation  |  |
| UAP | 1 (9.1%) |
| NSTEMI | 7 (63.6%) |
| STEMI | 3 (27.3%) |
| Time from presentation to PCI (n=9) |  |
| < 24 hours | 7 (63.6%) |
| 24-48 hours | 1 (9.1%) |
| >48 hours | 3 (27.3%) |
| Hypertension (n=11) | 8 (72.7%) |
| Diabetes mellitus (n=11) | 1 (9.1%) |
| Dyslipidaemia (n=11) | 8 (72.7%) |
| Previous CABG or PCI | 1 (9.1%) |
| Absolute neutrophil count (x 103/mL) (n=10) | 6.7 (±2.4) |
| Baseline hs-TnT (ng/L) (n=10) | 917.5 (±2104.6) |
| Number of diseased vessels (n=11) |  |
| One  | 5 (45.5%) |
| Two  | 2 (18.2%) |
| Three | 4 (36.4%) |

UAP – unstable angina pectoris, NSTEMI – non-ST elevated myocardial infarction, STMEI – ST elevated myocardial infarction, PCI – percutaneous coronary intervention, CABG – coronary artery bypass graft, hs-TnT – high sensitivity troponin T.

**Supplementary Table 3: Baseline neutrophil-derived product levels were not different between colchicine and no treatment groups.**

|  |  |  |
| --- | --- | --- |
|  | **SAP** | **ACS** |
|  | **No treatment** | **Colchicine** | **p value** | **No treatment** | **Colchicine** | **p value** |
| **NETs (%)** | 0.064±0.043 | 0.055±0.053 | 0.53 | 0.239±0.164 | 0.170±0.102 | 0.20 |
| **NE (ng/mL)** | 133.40±33.13 | 132.00±26.12 | 0.80 | 213.10±61.70 | 195.70±46.13 | 0.31 |
| **MPO (ng/mL)** | 127.20±35.14 | 127±38.15 | 0.63 | 171.53±44.21 | 157.80±29.66 | 0.43 |

ACS – acute coronary syndrome, MPO – myeloperoxidase, NE – neutrophil elastase, NETs – neutrophil extracellular traps, SAP – stable angina pectoris.



**Supplementary Figure 1: Peripheral venous levels of neutrophil-derived products are not impacted by colchicine treatment.** Venous blood was collected pre-PCI (black circles) and post stenting (white circles) and levels of (**A, B**) Neutrophil extracellular traps (NETs), (**C, D**) neutrophil elastase (NE) and (**E, F**) myeloperoxidase (MPO) in patients with (**A, C, E**) stable angina pectoris (SAP) or (**B, D, E**) acute coronary syndrome (ACS).

****

**Supplementary Figure 2: Colchicine treatment has no impact on NETosis in neutrophils isolated from healthy participants.** Neutrophils were isolated and treated with 25 nM colchicine for 1.5 h before NETosis was measured using a fluorescent plate-based method in (**A**) unstimulated cells or in cells stimulated with (**B**) PMA or (**C**) ionomycin.



**Supplementary Figure 3: Colchicine treatment does not impact on classical mediators of NETosis in neutrophils isolated from patients with ACS.** Neutrophils from patients with ACS were isolated and treated with 25 nM colchicine (white bars) or control (black bars) for 1.5 h and relative ATP levels were quantified in neutrophils stimulated with (**A**) PMA or (**B**) ionomycin. Error bars represent standard deviation of the mean.